The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis

• Published in: Cancer treatment reviews 2024-09, Vol.129, p.102787, Article 102787
• Main Authors: Zhang, Yaowen, Chen, Junru, Liu, Haoyang, Dai, Jindong, Zhao, Junjie, Zhu, Sha, Zhang, Xingming, Liang, Jiayu, Hu, Xu, Zhao, Jinge, Liu, Zhenhua, Shen, Pengfei, Sun, Guangxi, Zeng, Hao
• Format: Article
• Language: English
• Subjects: Carcinoma, Renal Cell - drug therapy; Carcinoma, Renal Cell - immunology; Carcinoma, Transitional Cell - drug therapy; Carcinoma, Transitional Cell - immunology; Clinical outcomes; Drug-Related Side Effects and Adverse Reactions - epidemiology; Drug-Related Side Effects and Adverse Reactions - etiology; Humans; Immune checkpoint inhibitors; Immune Checkpoint Inhibitors - adverse effects; Immune-related adverse events; Incidence; Kidney Neoplasms - drug therapy; Kidney Neoplasms - immunology; Kidney Neoplasms - pathology; Renal cell carcinoma; Urologic Neoplasms - drug therapy; Urologic Neoplasms - immunology; Urologic Neoplasms - pathology; Urothelial carcinoma
• ISSN: 0305-7372; 1532-1967; 1532-1967
• DOI: 10.1016/j.ctrv.2024.102787

•Summarized the incidence of irAEs by tumour types, irAE grades and ICI agents in RCC and UC.•Patients with irAEs had better treatment responses and survival outcomes.•Cutaneous irAEs, thyroid irAEs and grade ≤ 2 irAEs related to better survival benefits.•Glucocorticoids use for irAEs had noinfluence on clinical outcomes. This study aimed to summarize the occurrence of immune-related adverse events (irAEs) and further evaluate their association with clinical outcomes in patients with advanced renal cell carcinoma (RCC) and urothelial carcinoma (UC) treated with immune checkpoint inhibitors (ICIs). A comprehensive search of PubMed, Embase, and the Cochrane Library up to December 2023 was conducted to identify eligible studies. The details of irAEs and data regarding their correlation with clinical outcomes were extracted. R software was used for meta-analysis. A total of 27 studies involving 6148 patients with RCC or UC were included. The pooled overall incidence for any-grade and grade ≥ 3 irAEs was 44.2 % (95 % CI: 38.1 %-50.5 %) and 15.7 % (95 % CI: 11.4 %-21.1 %), respectively. Compared to those without any irAEs, patients with irAEs showed improved PFS (HR = 0.44, 95 % CI: 0.35–0.56, p